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Embryonic stem cells (ESCs) and induced pluripotent stem cells (IPSCs) hold great promise for the 
therapeutic treatment of human diseases, but their functional similarity, their stability and especially 
the mechanism underlying their derivation are not yet clearly explained.  
Embryonic development in mammalians is a very exciting process that starts with the generation of 
a totipotent unicellular zygote, continues with a series of precisely coordinated cellular differentiation 
processes, in which the newly generated cells undergo a progressive restriction of developmental 
potential, and is finally fully accomplished with the generation of an organism composed of more than 
200 different highly specialized unipotent cell types. This extremely complex process is coordinated 
not only through tissue-specific transcriptional regulatory proteins, but also by modifications of 
higher-order chromatin structures accompanied by changes of the chromatin organization at the level 
of individual genes. 
Nevertheless, subsets of self-renewing multipotent and unipotent cells, the so-called stem cells, are 
set aside at various steps of development and have been identified and described in several mammalian 
tissues. They are characterized by their ability to self-renew and to differentiate into a diverse range of 
specialized cell types: act as a repair system for the body, replenish specialized cells, and maintain the 
normal turnover of regenerative organs, such as blood, skin, or intestinal tissues. 
Embryonic stem cells (ESCs) are a very particular group of pluripotent stem cells, which can be 
isolated from the inner cell mass of blastocyst stage embryos and possess the capacity to contribute to 
the formation of all cells of an adult organism. In reality, the fact that stable and self-renewing 
pluripotent ESC lines can be derived from pre-implantation embryos is very interesting, because, in 
vivo, pluripotent cells in early embryos proliferate only for a very short time and become cells with a 
more restricted developmental potential; ESCs are therefore considered a cell culture artifact. Their 
main characteristic in vitro is that they can self-renew indefinitely while maintaining their pluripotent 
state, a condition that is sustained through a specific transcriptional hierarchy that controls the process 
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of self-renewal. A very fascinating scientific challenge is the elucidation of how cells with such 
capacities are established and propagated. 
ESCs are not homogeneous, every individual cell exhibits variable expression levels of 
pluripotency factors, for example Nanog, and also have distinct probabilities of self-renewal, which 
leads to the assumption that they may also have differing developmental potential. Their capacity to be 
able to generate all cells from the body makes them a valuable tool for future regenerative medicine 
applications.  
The recent discovery that differentiated cells can be reprogrammed to pluripotency by transduction 
with four genes important for pluripotency, the so-called Yamanaka factors (Sox2, Oct4, Klf4 and  
c-Myc), not only widens our understanding of the concept of pluripotency but also opens new ways to 
the efficient derivation of patient-specific, autologous stem cells, which possess considerable potential 
for the study and for the treatment of human diseases. Using mouse models, it was recently shown that 
skin cells reprogrammed with the Yamanaka factors can be used to treat the symptoms of Parkinson’s 
disease [1] and sickle cell anemia [2]. Nonetheless, although the discovery of iPSCs is an incredible 
step forward in stem-cell research, at the moment this technology represents only the beginning of a 
long road. The protocols used for the generation of iPSCs are still linked to the use of viral vectors and 
oncogenes, which makes these cells currently more of a great research application than a therapeutic 
tool. Therefore, the necessity of creating these cells without permanent genetic modifications will 
determine in the near future the research in this field.  
However, before the real therapeutic potential of iPSCs can be fully exploited, it will be necessary 
to clearly understand the processes that maintain pluripotency in these cells and signal differentiation. 
It will also be necessary to clarify if iPSCs really have the same properties and potentials as embryonic 
stem cells, because they might differ in their abilities to differentiate in the same way that embryonic 
stem cells seem to.  
Furthermore, more extensive studies directed towards the identification of the best cell types for 
reprogramming are still necessary. Recent data from Eminli and colleagues found for example that 
progenitors and hematopoietic stem cells are far more amenable to reprogramming into iPSCs than are 
differentiated cells [3]. 
The optimization of the reprogramming technology is in full progress, the main goal being the 
generation of transgene free iPSCs. Different approaches are currently being tested, making use of 
transient factor delivery with vectors that do not integrate into the genome (adenoviruses, transfected 
plasmids, DNA minicircles) or through the use of expression-excision systems (Cre-LoxP) and lately 
by using transposons. A further approach towards alternatives to replace virally transduced 
transcription factors is the use of small chemical compounds to control the signaling cues responsible 
for reprogramming. Indeed, several reports described the possibility to reprogram fibroblasts to iPSCs 
through chemical complementation of some of the reprogramming factors [4,5]. 
Last but not least, besides the four Yamanaka factors, other factors such as LIN28 [6], Esrrb [7] and 
Nr5a2 [8] were also found to participate in reprogramming. The future will show how many - more or 
less potent - new genes are able to cooperate in the conversion of differentiated cells towards 
pluripotency. In this context, it is worth mentioning the recent discovery that it is possible to directly 
transdifferentiate mouse skin cells into functional murine nerve cells, without first generating iPSCs, 




and therefore directly inducing one cell type to become a completely different cell type by defined  
factors [9].  
Our current knowledge of the genetic mechanisms regulating pluripotency and differentiation of 
ESCs and iPSCs are nevertheless not yet exhaustive. Some factors are since many years known to play 
an important role in maintenance of pluripotency, for example, LIF (leukaemia inhibiting factor) that 
activates the transcription factor STAT3, an essential component for the maintenance of the 
undifferentiated state of murine ES cells. Nevertheless, the genes targeted by STAT3 are not yet well 
characterized, and recent works showed that unknown genes acting downstream of this transcription 
factor are of great interest in this context [10]. The same holds true for other factors like Nanog, which 
is considered the key to pluripotency. However, its role is puzzling because it can be deleted from 
ESCs without causing them to differentiate, and it was astonishingly not present among the collection 
of genes that can induce reprogramming to iPSCs [11]. Nevertheless, Silva et al. could show that 
Nanog does help to separate incompletely reprogrammed cells from fully reprogrammed ones and is 
absolutely required for the acquisition of pluripotency. Cells that are not able to produce Nanog can 
still undergo the early stages of the reprogramming process, but cannot proceed to full pluripotency 
[12]. 
In a similar way, the controlled differentiation of pluripotent cells towards pure populations of 
precursors and terminally differentiated cells is also not yet completely understood. Although many of 
the conditions that facilitate lineage commitment and differentiation are known, a more precise 
knowledge of the genetic programs involved is a must before using stem cell therapies in humans, 
since undifferentiated stem cells transplanted in mice can cause tumor formation.  
The field of stem cell research is one of the grand challenges of our times and is fortunately 
strengthened through the advent of the modern high throughput technologies together with molecular 
biology, genetics, and pharmacology. The switch to the post-genomic era opens new possibilities in 
understanding the mechanism ruling cell fate. The integrative analysis of gene expression data, 
together with information on protein synthesis and modification will allow a much closer 
understanding of the cellular processes than the simple gene expression changes as measured today.  
The possibility to generate patient specific iPSCs allows, for example to step beyond analyzing 
generic genomes, and to understand which genetic differences between individuals are the keys for 
predispositions to certain diseases.  
The clarification of the correlations between pluripotency, epigenetics and DNA damage repair also 
need extensive studies. It is known that proliferating cells possess molecular mechanisms for sensing 
and repairing DNA lesions that occur at specifically DNA damage-activated cell cycle checkpoints. 
Unclear are the mechanisms present in progenitors of differentiated cells, in which cell cycle arrest is a 
critical signal to trigger the differentiation program, or in terminally differentiated cells, which are 
typically post-mitotic. How DNA lesions are detected, processed and repaired in these cells, remains 
an open question. Recent data indicated that cells undergoing reprogramming experience yet 
uncharacterized genotoxic stress [13], similar to that shown for oncogene activation in both in vitro 
and in vivo systems [14-16]. This observation highlights the existence of obstacles for the therapeutic 
potential of this approach and certainly calls for further molecular research to elucidate the close 
relationship between genome stability and cell reprogramming. 




With this Special Issue of the journal Genes, we aim at presenting recent research and 
developments on this very exciting topic. Special interest is given to reports on genes and pathways 
involved in the establishment and maintenance of natural and acquired pluripotency, in controlling the 
global and local chromatin organization in pluripotent cells, and in triggering reprogramming in 
somatic and adult stem cells. We further aim at presenting reports on the mechanism controlling the 
switch from pluripotency to differentiation towards defined populations of cells.  
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